{'fraction_non_alphanumeric': 0.035168195718654434, 'fraction_numerical': 0.07033639143730887, 'mean_word_length': 5.238095238095238, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Guideline summary: use of epoetin and darbepoetin in patients with cancer-2007 american society of clinical oncology/american society of hematology clinical practice guideline update.

Context An Update Committee of members from the full American Society of Clinical Oncology (ASCO) and American Society of Hematology (ASH) expert panel published this clinical practice guideline update (J Clin Oncol 26:132-149, 2008). The guideline update was approved by the ASCO Board of Directors on August 15, 2007, and the Executive Committee of ASH on August 14, 2007. The previous version of this guideline was published in 2002 (J Clin Oncol 20:40834107, 2002).